- A triple-action cancer jab, amivantamab, has shown "unprecedented" trial results, eradicating entire tumors in some patients, as reported by The Irish Times.
- The injection was tested on individuals with advanced cancer, primarily head and neck cancer, that had resisted previous chemotherapy and immunotherapy treatments.
- Dramatic changes were observed within weeks, with tumors shrinking or disappearing completely in 43 out of 102 patients, and 15 patients experiencing complete tumor eradication, according to The Guardian.
- Professor Kevin Harrington of the Institute of Cancer Research, London, stated that these are "unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy".
- The findings of this international trial, spanning 11 countries, will be presented at the American Society of Clinical Oncology (ASCO) conference.
- Amivantamab works by blocking proteins (EGFR and MET) that help cancers grow and evade treatment, while also activating the immune system to attack tumors.
- Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a very poor prognosis, as noted by The Mirror.
Cancer Jab Shows 'Unprecedented' Results
A new triple-action cancer jab, amivantamab, has shown "unprecedented" trial results by completely eradicating tumors in some patients with advanced, treatment-resistant cancers. This innovative injection, which blocks cancer-promoting proteins and activates the immune system, offers significant hope after 15 out of 102 patients experienced full tumor eradication, despite previous treatments failing.
Reporting Sources
5
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
